Correction: MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression

Ming-Hua Hu; Chen-Yang Ma; Xiao-Ming Wang; Chen-Dong Ye; Guang-Xian Zhang; Lin Chen; Jin-Guo Wang

doi:10.18632/oncotarget.28066

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression

PDF | How to cite

Oncotarget. 2021; 12:1859-1860. https://doi.org/10.18632/oncotarget.28066

Metrics: PDF 911 views | ?

ZMing-Hua Hu¹, Chen-Yang Ma¹, Xiao-Ming Wang¹, Chen-Dong Ye², Guang-Xian Zhang¹, Lin Chen¹ and Jin-Guo Wang¹

¹ Department of Surgery, Yijishan Hospital, Wannan Medical College, Wuhu 241001, P.R. China
² Department of Surgery, The Second Affiliated Hospital, Wannan Medical College, Wuhu 241001, P.R. China

Published: August 31, 2021

Copyright: © 2021 Hu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: The image in Figure 8, panel A is an accidental duplicate of the image in Figure 8, panel E. The corrected Figure 8, obtained using the original data, now shows the proper panel A. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:66922–66934. DOI: https://doi.org/10.18632/oncotarget.11877.

Figure 8: The VEGF-positive rate of transplanted tumors in nude mice among different groups detected by immunohistochemistry (× 200). (A) The blank group; (B) The miR-126 mimics group; (C) The miR-126 inhibitors group; (D) The si-EGFL7 group; (E) The miR- 126 inhibitors + si-EGFL7 group.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28066

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: MicroRNA-126 inhibits tumor proliferation and angiogenesis of hepatocellular carcinoma by down-regulating EGFL7 expression